2022 World Conference on Lung Cancer (ePosters)-EP08.01-042. NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

EP08.01-042. NEPTUNE China Cohort: First-Line Durvalumab + Tremelimumab versus Chemotherapy in Chinese Patients with Metastatic NSCLC

Back to course

Pdf Summary

This document reports the results of a prespecified exploratory analysis from the Phase 3 NEPTUNE study, which assessed the efficacy and safety of first-line durvalumab and tremelimumab (DT) in Chinese patients with metastatic non-small-cell lung cancer (NSCLC). The study included a China cohort of 160 patients enrolled at 10 centers in China.<br /><br />The analysis revealed that first-line DT showed a trend towards improved overall survival (OS) compared to chemotherapy (CT) in both the PD-L1 TC 1% population and the intention-to-treat (ITT) population in Chinese patients with metastatic NSCLC. Progression-free survival (PFS) was similar between treatments in both populations, but the 24-month OS and 12-month PFS rates favored DT, indicating benefit in the tails of the survival curves. DT was also well tolerated, with no new safety signals identified.<br /><br />NEPTUNE compared two treatments for metastatic NSCLC: CT and a combination of two immunotherapies, durvalumab and tremelimumab. The combination therapy helps the immune system identify and attack cancer cells. Previous trials have shown that this combination therapy may benefit patients with low levels of PD-L1.<br /><br />The findings of the analysis suggest that Chinese patients with metastatic NSCLC, especially those with low PD-L1 levels, may have a better chance of living longer with DT compared to CT. The results also demonstrate that DT is well tolerated with manageable side effects.<br /><br />It's important to note that the analysis was exploratory, and no adjustments were made for multiplicity. The primary analysis focused on patients with PD-L1 TC 1%, while secondary analyses included all patients in the China cohort.<br /><br />Overall, these results provide valuable insights into the efficacy and safety of first-line DT treatment for Chinese patients with metastatic NSCLC, highlighting the potential benefits of this therapy in improving survival outcomes.

Asset Subtitle

Ying Cheng

Meta Tag

Speaker Ying Cheng

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

Phase 3 NEPTUNE study

durvalumab

tremelimumab

metastatic non-small-cell lung cancer

Chinese patients

efficacy

safety

overall survival

progression-free survival

immunotherapies